. 2021 Jun 23;26(10):825–e1674. doi: 10.1002/onco.13853

Table 1.

Best response

Response	Investigator assessment (n = 44)	Patients, %^a
Overall response rate (95% CI)^b	10	22.7 (11.5–37.8)
Clinical benefit rate (95% CI)	25	56.8 (41.0–71.7)
Best response^b
Complete response	1	2.3
Partial response	9	20.5
Stable disease	15	34.1
Progressive disease	8	18.2
Could not be evaluated^c	11	25.0

^{^a}

Percentages may not total 100 because of rounding.

^{^b}

Overall response rate and best response were derived from the responses as assessed at specific time points according to the RECIST version 1.1.

^{^c}

Presumed to be most likely related to progressive disease as patients discontinued therapy for clinical progression prior to obtaining image confirmation.

Abbreviation: CI, confidence interval.